Article Correctness Is Author's Responsibility: NIH clinical trial of remdesivir to treat COVID-19 begins

(NIH/National Institute of Allergy and Infectious Diseases) A randomized, controlled clinical trial to evaluate the safety and efficacy of the investigational antiviral remdesivir in hospitalized adults diagnosed with coronavirus disease 2019 (COVID-19) has begun at the University of Nebraska Medical Center in Omaha. The trial regulatory sponsor is the National Institute of Allergy and Infectious Diseases. This is the first clinical trial in the US to evaluate an experimental treatment for COVID-19, the respiratory disease first detected in December 2019 in China.